QBI 139

Drug Profile

QBI 139

Alternative Names: QBI-139

Latest Information Update: 28 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Quintessence Biosciences
  • Class Antineoplastics; Endoribonucleases; Ribonucleases
  • Mechanism of Action Ribonuclease stimulants; RNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 28 Apr 2016 Phase-I development is ongoing in USA
  • 28 Apr 2016 QBI 139 is available for licensing as of 28 Apr 2016. http://www.quintbio.com/
  • 06 Apr 2011 Phase I development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top